Showing 1,021 - 1,040 results of 106,654 for search '(( a we decrease ) OR ( 50 ((((ms decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.34s Refine Results
  1. 1021
  2. 1022
  3. 1023

    A flow diagram of the study entry. by Sakiko Fukui (387048)

    Published 2025
    “…Criteria included: at least six months’ residency before death, ability to eat orally during the study period, and death within the facility. We created a time-series dataset for 69 participants, documenting their average weekly food intake (on a scale of 0-10). …”
  4. 1024
  5. 1025
  6. 1026

    Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes by Bruce A. Perkins (312635)

    Published 2015
    “…</p><p>Methods</p><p>In an 8-week single-arm open-label pilot study of empagliflozin, we compared ambulatory glucose profiles produced from CGM data during 2-week intervals in a placebo run-in baseline period, end-of-treatment, and post-treatment. …”
  7. 1027
  8. 1028

    The Impact of Prophylactic Dexamethasone on Nausea and Vomiting after Thyroidectomy: A Systematic Review and Meta-Analysis by Zhenhong Zou (645858)

    Published 2014
    “…The meta-analysis demonstrated a significant decrease in the incidence of PONV (RR 0.52, 95% CI 0.43 to 0.63, <i>P</i><0.00001), the need for rescue anti-emetics (RR 0.42, 95% CI 0.30 to 0.57, <i>P</i><0.00001), post-operative pain scores (WMD –1.17, 95% CI –1.91 to –0.44, <i>P</i> = 0.002), and the need for rescue analgesics (RR 0.65, 95% CI 0.50–0.83, <i>P</i> = 0.0008) in patients receiving dexamethasone compared to placebo, with or without concomitant antiemetics. …”
  9. 1029

    Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review by Weixin Wu (714474)

    Published 2015
    “…</p><p>Methods</p><p>We conducted a retrospective review of 333 patients with metastatic prostate cancer treated with docetaxel at a comprehensive cancer center between October 7, 2004 and December 31, 2012. …”
  10. 1030
  11. 1031

    DataSheet1_The antimicrobial peptide Esc(1-21)-1c increases susceptibility of Pseudomonas aeruginosa to conventional antibiotics by decreasing the expression of the MexAB-OprM effl... by Carolina Canè (17274244)

    Published 2023
    “…We therefore investigated the underlying mechanism implemented by the peptide using a differential proteomic approach. …”
  12. 1032

    NTM cells treated with TGFβ1 show increased expression of COL1A1 and DNMT1 and decreased expression of RASAL1. by Fiona McDonnell (2636635)

    Published 2016
    “…</b> Upon investigation of mRNA expression of COL1A1, DNMT1 and RASAL1 by qPCR, we found that COL1A1 (P<0.05) and DNMT1 were increased and RASAL1 (P<0.05) was decreased in the cells treated with TGFβ1. …”
  13. 1033
  14. 1034

    Proteomic and Targeted Metabolomic Studies on a Silkworm Model of Parkinson’s Disease by Feifei Zhu (480283)

    Published 2022
    “…Proteomics analysis revealed a major downregulation of nearly 50 structural proteins constituting cuticles and microfilaments, indicating mechanical damage in the silkworm tissues. …”
  15. 1035
  16. 1036

    Low apolipoprotein A-I levels in Friedreich’s ataxia and in frataxin-deficient cells: Implications for therapy by QingQing Wang (1389630)

    Published 2018
    “…One also showed that there was no difference in serum Apo-A-I levels in FA when compared with controls. Using a highly specific stable isotope dilution mass spectrometry-based assay, we demonstrated a 21.6% decrease in serum ApoA-I in FA patients (134.8 mg/dL, n = 95) compared with non-affected controls (172.1 mg/dL, n = 95). …”
  17. 1037
  18. 1038

    TMD residues decrease sensitivity. by Ákos Nemecz (356830)

    Published 2017
    “…Glu residues are color coded based upon effect, with residues in red producing a significant decrease in pH<sub>50</sub>, and in yellow, an insignificant or weak effect, whereas the dark purple and magenta for His residues are synonymous to the red of Glu residues. …”
  19. 1039

    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

    Published 2015
    “…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”
  20. 1040